For the year ending 2025-12-31, AQST had $49,623K increase in cash & cash equivalents over the period. -$52,994K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -83,784 |
| Depreciation and amortization | 548 |
| Share-based compensation | 7,624 |
| Amortization of debt issuance costs and discounts | 10,995 |
| Gain on contract termination | 0 |
| Other, net | -1 |
| Trade receivables and other receivables, net | 10,372 |
| Inventories | 126 |
| Prepaid expenses and other assets | -698 |
| Accounts payable | 19,523 |
| Accrued expenses and other liabilities | 3,032 |
| Deferred revenue | -571 |
| Net cash used for operating activities | -52,432 |
| Capital expenditures | 562 |
| Net cash used for investing activities | -562 |
| Proceeds from issuance of common stock under public equity offering-atm, net | 21,194 |
| Proceeds from common stock issued under public equity offering, net | 79,460 |
| Proceeds from exercise of warrants, net | 1,430 |
| Proceeds from shares issued under employee stock purchase plan | 110 |
| Proceeds from exercise of stock options | 1,270 |
| Repayment of debt principal including lease liabilities | 26 |
| Payments for royalty obligations | 11 |
| Payments for taxes on share-based compensation | 810 |
| Net cash provided by financing activities | 102,617 |
| Net increase in cash and cash equivalents | 49,623 |
| Beginning of period | 71,546 |
| End of period | 121,169 |
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)